Trial · NCT06253221
Registered outcomes20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 20
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from baseline in Valsalva left ventricular outflow tract (LVOT) (VLVOT) gradient | At Week 28 | |
| Secondary | Change from baseline in resting LVOT gradient | At Week 28 | |
| Secondary | Change from baseline in post-exercise peak LVOT gradient | At Week 28 | |
| Secondary | Change from baseline in maximal wall thickness | At Week 28 | |
| Secondary | Change from baseline in ratio between early mitral inflow velocity and mitral annular early diastolic velocity (E/e') | At Week 28 | |
| Secondary | Proportion of participants achieving an increase from baseline to Week 28 in peak oxygen uptake test (pVO2) | From baseline up to Week 28 | |
| Secondary | Proportion of participants achieving a reduction from baseline to Week 28 in maximal LVOT gradient to < 30 mmHg | From baseline up to Week 28 | |
| Secondary | Proportion of participants with at least 1 class improvement in New York Heart Association (NYHA) class from baseline to Week 28 | From baseline up to Week 28 | |
| Secondary | Proportion of participants with at least 1 grade improvement in mitral regurgitation at Week 28 | From baseline up to Week 28 | |
| Secondary | Number of participants with treatment-emergent adverse events (TEAEs) | Up to Week 218 | |
| Secondary | Number of participants with treatment-emergent serious adverse events (TESAEs) | Up to Week 218 | |
| Secondary | Change from baseline in electrocardiogram (ECG) (QT interval) | At Week 28 | |
| Secondary | Number of participants with left ventricular ejection fraction (LVEF) ≤ 30% | Up to Week 200 | |
| Secondary | Number of participants with LVEF < 50% | Up to Week 200 | |
| Secondary | Trough observed plasma concentration (Ctrough) | Up to Week 200 | |
| Secondary | Post-dose plasma concentration of mavacamten | Up to Week 200 | |
| Secondary | Maximum observed concentration (Cmax) | Up to Week 200 | |
| Secondary | Area under the concentration-time curve (AUC) | Up to Week 200 | |
| Secondary | Proportion of participants who evaluate taste and swallowability as neutral or better using taste and swallowability scales | At Day 1 and Week 11 | |
| Secondary | Change from baseline in the Hypertrophic Cardiomyopathy Symptom Questionnaire - Shortness of Breath (HCMSQ SoB) domain | At Week 28 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06253221/registered